Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lundbeck makes new appointment to reinforce development

Lundbeck makes new appointment to reinforce development

9th September 2009

Lundbeck has revealed the details of a new appointment it has made in order to strengthen the process and outcomes of the clinical trails it executes.

The firm has recruited the expertise of Karin Hamberg, 48, who is now its new vice-president with the global responsibility for the successful execution of its clinical studies.

Ms Hamberg counts Leo Pharma and Lifecycle Pharma among her former employers and holds a degree in medicine. She has worked in various roles, including managerial, vice-president and overseer of trials.

“It is becoming increasingly important […] that we not only design and plan our studies in the optimum manner, but that we also execute them in the best possible way in practice,” explained Anders Gersel Pedersen, executive vice-president of drug development at Lundbeck.

The firm revealed last month that the Food and Drug Administration has approved Sabril (vigabatrin), marking the first time it has endorsed a drug for infantile spasms.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.